Study of Synbiotic Supplementation Effects on Insulin, TNF-alpha, and Gut Microbiota in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease MAFLD

What this Trial Is About

Researchers are studying the effects of synbiotic supplementation on patients with Metabolic Dysfunction-Associated Fatty Liver Disease MAFLD, a type of fatty liver condition linked to metabolic issues like obesity and diabetes. This research aims to see if synbiotics can change metabolic profiles, insulin levels, inflammatory marker TNF-alpha, and gut microbiota in these patients. The study is designed as a randomized controlled trial to analyze these effects in adults aged 25 to 55 years. Participants are divided into two groups one receives RILLUS, a synbiotic supplement containing specific probiotic bacteria and prebiotic fibers, while the other receives a placebo that looks similar but lacks the live bacteria. Both groups will take two tablets daily for 12 weeks. Hospital visits for control and follow-up occur every 28 days over about four months. Participants will also keep logs to track supplement intake and food consumption. Throughout the study, participants will undergo various assessments including blood tests for hematology, metabolic profiles, insulin, TNF-alpha, and C-reactive protein at three months. Gut microbiota diversity will be evaluated at four months. The researchers will monitor compliance and collect data to understand how synbiotic treatment may influence these health markers. The total study duration for each participant is about four months, including supplementation and follow-up periods.

Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis